Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 702 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR Grieving for Your Old Life After Cancer September 10, 2020 FOCUS4: Learning from a landmark clinical trial April 25, 2023 Patients with Advanced Hodgkin’s Lymphoma Treated with Brentuximab Vedotin Plus AVD... July 19, 2022 Opinion: ‘We can’t afford to stop now’ November 30, 2020 Load more HOT NEWS New Research in Treating Non-Small Cell Lung Cancer: 2022 North America... Two Years After Cancer Diagnosis, Swimmer Rikako Ikee Has Qualified For... Fears breast cancer progress could stall due to COVID-19 backlog The Obesity Paradox: It Increases Diabetes Risk But Can Help Cancer...
